Australia shaken by complementary medicines recall
The TGA first became aware of Pan Pharmaceuticals after reports of adverse reactions to its anti-travel sickness product, Travacalm, in January. Faulty batches of the product were responsible for 19 people being admitted to hospital and 68 people having serious adverse reactions. The TGA subsequentl...
Gespeichert in:
Veröffentlicht in: | The Lancet (British edition) 2003-05, Vol.361 (9370), p.1710-1710 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The TGA first became aware of Pan Pharmaceuticals after reports of adverse reactions to its anti-travel sickness product, Travacalm, in January. Faulty batches of the product were responsible for 19 people being admitted to hospital and 68 people having serious adverse reactions. The TGA subsequently found that some batches of the tablets contained up to seven times the amount of the active ingredient-hyoscine hydrobromide. |
---|---|
ISSN: | 0140-6736 1474-547X |
DOI: | 10.1016/S0140-6736(03)13384-3 |